Q-omics provides the consensus-scored ACP7 profile across patient tissues and cancer cell-line models. ACP7 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ACP7 is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, ACP7 RNA expression shows 12,976 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LUSC, and LSCC as cancer lineages where ACP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACP7 survival associations across molecular data types. ACP7 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACP7 RNA expression–survival associations across cancer types. High ACP7 expression shows unfavorable associations in KIRC, LUAD, BRCA, MESO, LGG and STAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ACP7 RNA expression.
This table summarizes ACP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for ACP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACP7 shows lower tumor expression in PRAD and higher tumor expression in LUSC, BLCA, HNSC, UCEC and BRCA. The LUSC box plot shows higher ACP7 RNA expression in tumor versus normal tissue (log2 FC = +2.037, t-test p < 0.001).
This table shows molecular features associated with ACP7 in patient tissues and cancer cell lines. In patient samples, ACP7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ACP7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
